tacrolimus and Hemangioendothelioma

Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA) are rare infiltrative vascular tumors. Currently, no standard treatment regimens exist for KHE/TA. The purpose of our study was to evaluate the efficacy and safety of topical application of tacrolimus for superficial KHE/TA. We examined six patients with superficial KHE/TA. All patients were treated with tacrolimus 0.1% ointment twice daily for at least 12 months. The response rate was 100%, including three nearly complete remissions. Only one patient experienced local pruritus during treatment. The data constituted an intriguing rationale for clinical trials of topical tacrolimus in the treatment of superficial KHE/TA.

Topics: Administration, Cutaneous; Biopsy; Child, Preschool; Female; Hemangioendothelioma; Hemangioma; Humans; Infant; Kasabach-Merritt Syndrome; Male; Off-Label Use; Ointments; Photography; Pruritus; Sarcoma, Kaposi; Skin; Skin Neoplasms; Tacrolimus; Treatment Outcome

We report a patient with kaposiform haemangioendothelioma successfully treated with topical tacrolimus and compression bandaging.

Topics: Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Sarcoma, Kaposi; Tacrolimus